Characterizing Attack-Related Health Utility in Hereditary Angioedema Timothy Craig, DO¹; Kristen A. Cribbs, PhD MPH²; Shawn Czado³

Background

- Hereditary angioedema (HAE) is a rare, genetic disease characterized by debilitating swelling episodes in various parts of the body¹
- Health-state utilities are proxies for patient quality-of-life and important inputs for health economic models²
- As such, utilities facilitate the assessment of new medical technology impacts and guide healthcare decision-making³
- To date, no comprehensive assessments of health utilities in HAE have been conducted; this study aimed to fill this gap


Methods

- We conducted a systematic literature (SLR) on economic outcomes, including utility values, among patients with HAE, including those using prophylactic and/or ondemand HAE therapies, in accordance with PRISMA guidelines
- We conducted searches in PubMed, Embase, and health technology assessment (HTA) websites
- Article inclusion was limited to English peer-reviewed and grey literature published between January 1, 2007, and July 1, 2022
- Two independent reviewers assessed literature eligibility and abstracted data

References

- PMCID: PMC5019462.

¹The Pennsylvania State University, College of Medicine, Allergy, Asthma and Immunology, Hershey, PA, USA; ³KalVista Pharmaceuticals, Inc., Cambridge, MA, USA



Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value Health. 2016 Sep-Oct;19(6):704-719. doi:

Briggs, A.H., Belozeroff, V. & Feeny, D. Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease. BMC Res Notes 12, 385 (2019). https://doi.org/10.1186/s13104-019-4413-y 4. Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Boysen HB, Caballero T. Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema. Patient Prefer Adherence. 2016 Sep 6;10:1699-707. doi: 10.2147/PPA.S100383. PMID: 27660419;

Bernstein JA, Tyson C, Relan A, Adams P, Magar R. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks. J Manag Care Spec Pharm. 2020 Feb;26(2):203-210. doi: 10.18553/jmcp.2019.19217. Epub 2019 Dec 16. PMID: 31841366. Lo SH, Lloyd A, Elkhalifa S, Sisic Z, van Nooten FE. Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. Pharmacoecon Open. 2022 Mar;6(2):231-239. doi: 10.1007/s41669-021-00302-6. Epub 2021 Sep 17. PMID: 34532843; PMCID: PMC8864034. Christopher Tyson, Anurag Relan, Phillippe Adams, Angela Haynes & Raf Magar (2019) Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks, Journal of Drug Assessment, 8:sup1, 22, DOI: 10.1080/21556660.2019.1658300

Results


Characteristic	n (%)
Total Number of Publications	66 (100)
Sample Size, number of patients	
Minimum	1
Maximum	737
Publication Type	
Peer-Reviewed	39 (59.1)
Conference Proceeding	14 (21.2)
Economic Report	13 (19.7)
Study Design	
Observational	42 (63.6)
Economic Analysis/Modeling	23 (34.8)
RCT	1 (1.5)
Study Location	
United States	28 (42.4)
Europe	25 (37.9)
Other	13 (19.7)
HAE Treatment Type, Studies*	
On-Demand Treatment	20
Prophylactic Treatment	15

Acknowledgements The authors thank Alkemi LLC contributors Betsy J. Lahue

editing

and Gio Shoushi, who assisted with abstract writing and

Disclosures



- disutility compared to attacks in other locations
- While treatment with on-demand therapy attenuates attack-associated disutility, we found that increasing attack severity substantially impacts patient utility
- New therapeutics that facilitate early treatment, thereby mitigating attack severity and hastening attack resolution, are needed to yield the greatest patient benefit

This study was sponsored by KalVista Pharmaceuticals, Inc. SC is an employee of KalVista Pharmaceuticals, Inc. No authors received compensation for their involvement in this research.



Please scan this QR code to view the poster after the congress



Radojicic C, Riedl MA, Craig TJ, et al. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy Asthma Proc. May 1 2021;42(3):S4-S10. doi:10.2500/aap.2021.42.210025 10.1016/j.jval.2016.06.001. PMID: 27712695.